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Transcription-independenta b s t r a c t
The tumor suppressor p53 is a transcription factor that in response to a plethora of stress stimuli
activates a complex and context-dependent cellular response ultimately protecting genome integ-
rity. In the last two decades, the discovery of cytoplasmic p53 localization has driven an intense
research on its extra-nuclear functions. The ability to induce apoptosis acting directly at mitochon-
dria and the related mechanisms of p53 localization and translocation in the cytoplasm and mito-
chondria have been dissected. However, recent works indicate the involvement of cytoplasmic
p53 also in biological processes such as autophagy, metabolism, oxidative stress and drug response.
This review will focus on the mechanisms of cytoplasmic p53 activation and the pathophysiological
role of p53’s transcription-independent functions, highlighting possible therapeutic implications.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The tumor suppressor TP53 has a central role in the biology of
the cell and represents one of the most efﬁcient barriers against
cancer development and progression. Embedded within a complex
and highly interconnected signaling pathway, p53 regulates key
cellular process such as DNA repair, metabolism, stemness, devel-
opment, inﬂammation, endocytosis and cell death. In addition to
cancer, it becomes a critical player also in ischemia, neurodegener-
ation and ageing, in response to a variety of stress stimuli [1].
p53 exerts its activity primarily at the transcriptional level,
directly binding to speciﬁc target sequences on DNA. Its timely
activation/inactivation upon stress depends on a complex reper-
toire of post-translational modiﬁcations and protein–protein inter-
actions to allow both direct and indirect transactivation of many
coding and non-coding genes. However, as for several other tran-
scription factors, it is now evident that the actions of p53, as well
as its localization, are not restricted to the nucleus and over the
years a clear transcriptional independent activity has emerged.One of the best characterized p53’s extra-nuclear activities is
the induction of apoptosis in the cytoplasm. Among the tumor sup-
pressive activities fostered by p53, apoptosis is undoubtedly the
most studied mechanism in vitro and in vivo; in particular p53 is
able to induce apoptosis through the intrinsic mitochondria-
mediated pathway, characterized by permeabilization of the outer
membrane (MOMP) leading to programmed cell death. p53 can
transcriptionally induce the pro-apoptotic members of this path-
way and repress anti-apoptotic genes, but it is also able to induce
apoptosis in a transcription-independent way. This alternative
route has been tightly investigated in the recent years and the
cytoplasmic and mitochondrial activities of p53 have been largely
deﬁned [2–4].
Out of the nucleus, p53 may also affect signal transduction,
metabolism, autophagy, vesicular trafﬁcking and cytoskeleton
organization. Other ﬁndings also sustain a possible role of cyto-
plasmic p53 in regulating stem cell expansion, as for example the
evidence that p53 is cytoplasmic in ES cells [5,6], where after
ROS exposure it can induce mitochondrial dependent apoptosis [6].
However while several mechanisms of p53 cytoplasmic activa-
tion towards the apoptotic route have been discovered to date,
most of the mechanisms regulating other arms of its cytoplasmic
activities remain largely unknown, as well as the possible exten-
sion in this context of the gain-of-function concept related to some
p53 missense mutants fostering oncogenesis.
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dysfunctions of p53, on the mechanisms behind its action in the
cytoplasm and its pathogenic implications pinpointing possible
hubs for therapeutic intervention.
2. Cytoplasmic localization: ‘‘should I stay or should I go’’
Activation of p53 involves a very complex cascade of events that
spans from protein oligomerization to a repertoire of post-transla-
tional modiﬁcations and protein interactions to accumulation in
speciﬁc cellular compartments. Although the key steps leading to
the full activation of the transcriptional program of p53 have been
intensively studied and deﬁned [7], most of the regulatory mecha-
nisms governing its cytoplasmic localization and activities remain
largely unknown, with the majority of reports regarding the tran-
scription-independent apoptotic context.
That said, a few requisites can be traced. The increase of p53
abundance in the cytoplasm is the ﬁrst required condition to trig-
ger the majority of the extra-nuclear activities of p53 [2,3,8]. How-
ever, several reports indicate that cytoplasmic p53 is able to exert
its action particularly after cell exposure to speciﬁc stimuli [2,9–
12]. These observations suggest that besides protein accumulation
and cytoplasmic shuttling, other events like speciﬁc post-transla-
tional modiﬁcations and protein–protein interactions could be crit-
ical also for p53 activities outside the nucleus.
The oligomeric state of p53 is a fundamental determinant of its
functions. While tetramerization has been shown to be essential
for p53 nuclear retention by masking its C-terminal nuclear export
signal (NES) [13], other forms of p53 could be important for its
nuclear export. Indeed, it has been demonstrated that the tran-
scription factor Foxo3a promotes p53 nuclear export and transcrip-
tion-independent apoptosis by fostering its interaction with the
nuclear-export protein CRM1 and p53 protein oligomerization
has been proposed as a mechanism governing Foxo3a mediated
nuclear p53 exclusion [14,15].
Among post-translational modiﬁcations, ubiquitylation has
been clearly linked to p53 subcellular localization. Poly-ubiquityla-
tion of p53 causes its proteasome-mediated degradation, while
mono- and multi-mono-ubiquitylation promotes its cytoplasmic
relocalization [14,16]. In particular, Marchenko et al. claimed the
role of the ubiquitylation as a speciﬁc signal for p53 mitochondrial
trafﬁcking (p53 lacks a mitochondrial targeting sequence). They
identiﬁed the MDM2-mediated p53 multi-mono-ubiquitylation
as the main signal governing p53 delivery to mitochondriaFig. 1. Regulation of p53 transcriptional-independent activities by post-translational
ubiquitylation control p53 mitochondrial translocation and activity after stress. After cell
this modiﬁed p53 is found enriched at mitochondria, where it can displace the anti-apopt
also Pin1-dependent HIPK2 activation that phosphorylates p53 on Ser46. By triggering Pi
promoting MDM2-mediated p53 mono-ubiquitylation and mitochondrial relocalization
MDM4, which, in turn, facilitates p53 interaction with anti-apoptotic Bcl-2 and cytochrnecessary for transcription-independent apoptosis induction after
stress [10] (Fig. 1). In cells, the relative stoichiometry of p53 and
MDM2, the main regulator of p53 protein abundance and also a
p53 target gene, plays critical role in switching from poly- to
mono-ubiquitylation, with low levels of MDM2 promoting mono-
versus poly-ubiquitylation of p53. Of note, upon arrival at the
mitochondria, the authors demonstrated that p53 undergoes active
de-ubiquitylation by resident HAUSP [10,17]. This has been the
ﬁrst demonstration that the cytoplasmic compartment is the
source of p53 that translocates to mitochondria thus opening the
debate about the role of nuclear exclusion process in this context.
Despite early investigations failed to ﬁnd causality between
other speciﬁc p53 modiﬁcations (e.g. acetylation and phosphoryla-
tion) and its pro-apoptotic role at mitochondria [18,19], recent
works unveiled a prominent role of these post-translational modi-
ﬁcation for p53-induced transcription-independent apoptosis.
Sykes et al. found that the Lys-120-acetylated form of p53 is
enriched at mitochondrial outer membrane, after DNA damage,
and that this modiﬁcation is not required for p53 mitochondrial
translocation but rather to displace the anti-apoptotic Mcl-1 from
the apoptosis effector Bak at the mitochondria [20]. Interestingly,
p53 acetylation was found to be required also for transcription-
independent apoptosis induced by HDAC inhibitors [21]. Recently,
we and others identiﬁed DNA-damage induced phosphorylation
of p53 on Ser46 as a key event for p53 mitochondrial translocation
[9,22]. In this context a pivotal role is played by the prolyl-isomer-
ase Pin1, a phospho-speciﬁc prolyl-isomerase that transduces post-
translational modiﬁcations into conformational changes relevant
for full activity of p53 and other proteins [23]. After DNA damage,
Pin1 promotes phospho-dependent cis-trans p53 isomerization
that lowers its afﬁnity for MDM2 with consequent activation of
nuclear p53 pro-apoptotic program [24–26]. Similar mechanisms
of p53 activation appear to govern its transcription-independent
activity in the cytoplasm. Mechanistically, the kinase HIPK2, acti-
vated by DNA-damage [27,28], phosphorylates p53 at Ser46 residue
recruiting Pin1 that leads to a p53 conformational change that
alters its afﬁnity for MDM2. Besides activating the nuclear pro-
apoptotic route of p53, this event results in an increase of the
mono-ubiquitylated pool of p53 that is engaged for mitochondrial
translocation [9,29]. Ser46-phosphorylation on p53 is maintained
at the mitochondria and mediates the anchorage of p53 to resident
MDM4 that, in turn, facilitates the interaction between p53 and the
anti-apoptotic protein Bcl-2 and the consequent MOMP induction
[22,30] (Fig. 1). Recent evidences suggest that this circuit could alsomodiﬁcations and protein–protein interactions. Acetylation, phosphorylation and
ular stress (DNA damage, oxidative stress and others), p53 is actively acetylated and
otic Mcl-1 from Bak causing consequent cytochrome c release. DNA damage induces
n1-dependent conformational change, this phosphorylation represents a key step in
. Here, after being deubiquitylated by HAUSP, phosphorylated p53 binds resident
ome c release.
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ylated HIPK2 interacts with Pin1 after DNA-damage. Pin1 mediates
a conformational change of HIPK2 that releases it from the inhibi-
tory E3 ubiquitin ligase Siah-1 thus triggering its stabilization,
pro-apoptotic activation and consequent nuclear and cytoplasmic
p53 activation [31] (Fig. 1). Pin1 has been found aberrantly
expressed in a variety of human tumors still expressing wild type
p53 [32,33]. It has been suggested that the higher levels of Pin1 in
these cells, by enhancing cytoplasmic apoptotic activity of p53,
could sensitize cancer cells to drugs activating wild type p53 min-
imizing undesired side effects in normal cells [9].
The HIPK2-p53Ser46-MDM4 recently emerged as an important
oncosuppressive axis in glioblastoma. The ubiquitin speciﬁc prote-
ase USP2a and MDM4, in fact, are highly expressed in good progno-
sis glioma tissues. Here USP2a stabilizes mitochondrial MDM4-
p53Ser46 interaction allowing efﬁcient p53-mediated mitochon-
drial apoptosis [34].
p53 possesses also intrinsic genetic properties that deﬁne its
ability to localize at mitochondria and to induce apoptosis. Dumont
et al. unveiled a functional difference between p53 codon 72 poly-
morphic variant Pro72 and Arg72, being the last more prone to
induce apoptosis [8]. This difference reﬂects the impaired ability
of p53 Pro72 variant to localize at mitochondria due to its reduced
binding to CRM1, essential for the nucleo-cytoplasmic shuttling
[14]. In line, we previously demonstrated that Arg72 is more phos-
phorylated on Ser46 and binds Pin1more efﬁciently as compared to
the Pro72 counterpart [25]. At mitochondria, Arg72 variant inter-
acts with resident proteins GRP75 and Hsp60. Since these proteins
are in intimate contact with pro-apoptotic factors it is possible that
p53 engages these interactions in order to alter the function of
these proteins and to consequently trigger apoptosis [35].3. Control of cell death: apoptosis and necrosis
One of the main outcomes of p53 activation by genotoxic stress
is the induction of apoptosis through the intrinsic mitochondria-
mediated pathway. This route implies the permeabilization of the
mitochondrial outer membrane (MOMP), which is regulated by
the proteins belonging to the Bcl-2 family and particularly induced
by the pro-apoptotic factors Bax or Bak [36].
The Bcl-2 family proteins all share the characteristic Bcl-2
homology domain (BH). The family is divided in anti-apoptotic
members, such as Bcl-2, Bcl-xL and Mcl-1, which contain BH1,
BH2, BH3 and BH4 domains, and the pro-apoptotic members,
which either contain BH1, BH2 and BH3 domains such as the
MOMP effectors Bax and Bak, or the BH3-only domain class such
as the activators tBid and Bim [37]. To efﬁciently induce apoptosis,
the effector proteins are activated by a conformational change and
an homo-oligomerization, which in turn leads to their transloca-
tion and insertion into the outer mitochondrial membrane to
generate pores that release pro-apoptotic factors from the mito-
chondrial intramembranous space (e.g. cytochrome c). The BH3-
only class of proteins covers the role of favoring such activation,
either by stimulating the oligomerization of Bak and Bax (tBid
and Bim proteins) or inhibiting the binding between anti-apoptotic
proteins and the effectors of apoptosis (Puma, Noxa and Bad pro-
teins) [38].
As said, MOMP is governed by p53. In the nucleus p53 induces
the transcription of pro-apoptotic Bcl-2 members including Bax,
Puma, Noxa and Bid, and represses the transcription of anti-apop-
totic genes including Bcl-2 and Bcl-xL [39–41]. In addition to these
activities, about twenty years ago, a p53 transcription-independent
route for MOMP has been discovered and starting from this in the
last years a lot of effort has been made in elucidating p53 pro-
apoptotic activities in the cytoplasm [42–44].The hallmark of transcription-independent apoptosis induction
by p53 is the stress-dependent accumulation of the protein in the
cytoplasm and mitochondria that directly activates the apoptosis
effectors Bax and Bak. Starting from this ﬁrst observation that
stress-induced p53 translocation to the mitochondria precedes
cytochrome c release and caspase activation [12], a great number
of studies performed in the recent years provided deﬁnitive proof
that this is a general mechanism of cell death responding to a wide
spectrum of p53 activating stresses (DNA damaging agents, acti-
vated oncogenes, hypoxia and others) and in different cellular
models, for example primary, immortal and malignant cells of
human and mouse origin [45–47]. Also in vivo observations on
p53 engineered proteins, either unable to translocate into the
nucleus [2] or with enhanced capability to translocate to the mito-
chondria, strengthened this idea [12]. All these observations,
together with the evidence that recombinant p53 can rapidly
induce MOMP and cytochrome c release from isolated mitochon-
dria in vitro, fully demonstrate that the p53 effect on MOMP is
direct [2].
Experiments with recombinant p53 allowed to unveil the com-
plex network of interactions that p53 entails at mitochondria. Puri-
ﬁed p53 is able to disrupt the complex formed by tBid, Bax and Bcl-
xL in vitro thus displacing the pro-apoptotic proteins from their
negative regulator [3,45–48]. This effect is indeed mediated by
direct interaction with Bcl-xL, as shown by several structural stud-
ies that conﬁrmed also the interaction with the other anti-apopto-
tic protein Bcl-2 [3,48–50]. p53 also interacts with Bak [3,4],
although the binding appears to be 10-fold weaker. It is not deﬁn-
itively proven whether these interactions happen in vivo, but it is
clear that stress-induced p53 is able to disrupt the complex
between Bak and its anti-apoptotic partner Mcl-1, by directly bind-
ing to Bak at the outer mitochondrial membrane, leading to oligo-
merization and activation of Bak and cytochrome c release
[4,48,50,51].
In addition to Bak, p53 seems to work like a direct activator of
Bax in absence of other proteins, by triggering its translocation to
mitochondria and oligomerization. These events lead consequently
to permeabilization of artiﬁcial membranes and isolated mitochon-
dria in vitro [2,11,52]. Nevertheless a stable p53-Bax complex has
never been detected [2]; for this reason, a ‘hit-and-run’ mechanism
was proposed to explain the direct activation of Bax by p53, involv-
ing a direct activity of p53 to promote conformational change of
Bax but without a stable interaction between the two proteins
[2]. For p53-Bax interaction the proline-rich domain at N-terminal
of p53 is required [2,52].
All the mentioned interactions can be declined in different ways
in order to explain the sequence of events that lead to apoptosis. In
particular, two different models have been proposed, the mito-
chondrial pathway and the cytosolic mechanism (Fig. 2).
Starting from the strong evidence of p53 localization at mito-
chondria, the ﬁrst model suggests that binding of p53 to Bcl-xL/
Bcl-2 neutralizes their anti-apoptotic effect leading to Bax or
Bak-dependent apoptosis [3]. Among the experimental evidences
in this direction there is the fact that all the p53 mutants unable
to bind to Bcl-xL/Bcl-2 also lack apoptotic activity [3,48]. Indeed
it was demonstrated that genotoxic stress is able to induce wild
type p53 binding to Bcl-2 at mitochondria and this binding results
in a reduced association of the anti-apoptotic protein with Bax,
that can therefore oligomerize and induce MOMP [53].
Conversely the other model, integrating the previous one, sus-
tains that the cytoplasmic pool of p53 is responsible for apoptosis
induction and also takes into account the control of transcription
exerted by nuclear p53. In unstressed cells, p53 is sequestered in
the cytoplasm by the interaction with Bcl-xL, thus keeping under
control the induction of apoptosis. Upon genotoxic stress, cytoplas-
mic Bcl-xL is bound by the BH3-only protein Puma rapidly
Post-translational
Fig. 2. Schematic representationof thedifferent routesof p53 induced transcription-independent cell-death.Theapoptosis program(On the left). Theﬁgure resumes thepathways
of cytoplasmic and mitochondrial apoptosis induced by p53. Cytoplasmic apoptosis (upper panel): under genotoxic stress activated p53 rapidly regulates the expression of
several apoptosis-relatedgenes; among them, increased levelsofPumaare able to releasep53 fromapre-existingcomplexwithBcl-xL. Free-activatedp53 in thecytoplasmwitha
’hit-and-run’ model binds Bax and promotes its mitochondrial translocation and homo-oligomerization, thus inducing mitochondrial membrane permeabilization and
cytochrome c release. Mitochondrial apoptosis (lower panel): under cell death stimuli p53 is activated, translocates to the mitochondria where, through binding the anti-
apoptotic factors Bcl-xL/Bcl-2 and Mcl-1, allows Bak release, prompting its homo-olDespite early investigations failed igomerization that forms pores on mitochondrial outer
membrane and induces cytochrome c release. The p53 necrosis program (On the right). ROS induce p53 activation and itsmitochondrial translocation. In themitochondrialmatrix
p53 interacts with cyclophilin D inducing VDAC oligomerization and PTP pore formation. These events cause H2O intake, swelling of mitochondria and necrotic cell death.
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activate monomeric Bax in the cytoplasm [51]. Notably however, it
has been demonstrated that p53-induced transcription-indepen-
dent apoptosis happens also in the absence of Puma [51,54,55].
The intrinsic pathway of apoptosis fostered by p53 causes the
activation of the executioner caspases [56]. These effector caspas-
es, including caspases-3, -6 and -7, cleave key substrates within the
cell in order to carry out the apoptotic process [57]. In a recent ele-
gant work, Murphy and colleagues performed a mass spectrometry
analysis for p53 interactors at mitochondria and identiﬁed pro-cas-
pase-3 as a novel binding partner of p53; interestingly it was dem-
onstrated that this interaction was able to enhance caspase-3
activation. Also mutant p53 retains the capability to bind cas-
pase-3, but in this case the effect is the inhibition of pro-caspase-
3 activation, which is protected from cleavage mediated by
upstream caspases with the ﬁnal result of impairing the execution
of apoptotic cell death [58].p53 activities at mitochondria are not only restricted to the reg-
ulation of apoptosis. Recently a new role of p53 has been described
in inducing necrotic cell death [59]. In response to many insults
and in direct relation to the strength of the stimulus, it has been
demonstrated that p53 can induce necrosis instead of apoptosis.
Necrosis is an irreversible route leading to cell death due to bioen-
ergetic failure, mainly driven by excess cytosolic Ca2þ and ROS
levels generated during oxidative damage and released by mito-
chondria during the mitochondrial permeability transition (mPT).
Interestingly, upon oxidative stress p53 accumulates in the mito-
chondrial matrix and binds directly to cyclophilin D, the key regu-
lator of the mitochondrial permeability transition pore (PTP)
whose opening is able to induce necrosis via mPT. In accordance
with this it has been demonstrated by several reports that p53
can change the oligomeric state of the inner membrane protein
VDAC, leading to cytochrome c release even in the absence of
Bax and Bak [59] (Fig. 2). The mechanism has been reported to
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were reproducible also in HCT116 cancer cells, thus indicating that
necrosis could also happen in cancer development. Although the
ability of p53 to localize at the mitochondrial outer membrane
thanks to the interaction with the resident BH3-containing pro-
teins is clear, the mechanism of p53 entry in the mitochondrial
matrix is still unknown and not dependent from a mitochondrial
entry sequence of which the protein is devoided [10].
4. Regulation of Autophagy by p53
Macroautophagy (generally referred to as autophagy) is a con-
served catabolic pathway evolved to deliver superﬂuous proteins
and damaged organelles to lysosomes for degradation and repre-
sents an essential process for survival under unfavorable metabolic
conditions (e.g. nutritional stress) [60]. Reported to be involved in
numerous physiological processes and in multiple pathological
conditions from neurodegeneration to cancer, autophagy is able
to drive the choice between cell survival and cell death, thus play-
ing an important role in cancer development. In this context,
autophagy may have a pro-survival effect in conditions of mild
nutritional stress, while it can lead to cell death when taken to
extremes. Several genetic/epigenetic alterations associated with
cancer development negatively regulate autophagy, suggesting
that basal autophagy may function as a tumor suppressive mecha-
nism. Conversely, autophagy may represent an important way to
escape cell death for tumors exposed to a challenging microenvi-
ronment or subjected to chemotherapy [61,62].
In the recent years it has been demonstrated that p53 can con-
trol the process of autophagy both positively and negatively. When
exposed to stress, nuclear p53 can induce autophagy by inhibitingFig. 3. Cytoplasmic p53 regulates key metabolic pathways and the oxidative stress re
internalization in stimulated cells, thus promoting its lysosomal degradation. On the oth
dependent vesicular trafﬁcking, thus prolonging EGF pathway activation. (B) Cytoplasm
pathway (PPP) and inhibits their activity. Via inhibition of the PPP, cytoplasmic p53 fo
mitochondria. (C) Cytoplasmic p53 is able to inhibit autophagy, in contrast with what is
still lacking.the master negative regulator of autophagy, the mTOR protein
kinase, acting at multiple levels of the AMPK-mTOR axis. First of
all, p53 can upregulate the transcription of mTOR negative modu-
lator TSC2 (tuberous sclerosis 2). Nuclear p53 also induces the
transcription of the beta 1 and beta 2 subunits of AMP-activated
protein kinase (AMPK), an evolutionarily conserved sensor of cellu-
lar energy levels that phosphorylates and thus activates TSC1 and
TSC2. Moreover p53 enhances sestrins 1 and 2 transcription, two
main activators of AMPK [63–65] (Fig. 3).
Another important transcriptional target of p53 involved in
autophagy modulation is DRAM (damage-regulated autophagy
modulator), a lysosomal protein that induces macroautophagy
and is also able to regulate cell death [66,67]. Interestingly, the role
of DRAM unveils the tight connection existing between autophagy
and apoptosis, which can partially explain the complexity of their
mutual regulation and the outcome of nuclear p53 activation.
Indeed, regarding this crosstalk, another pro-autophagic role of
p53 is played through the members of the Bcl-2 protein family,
whose transcription is repressed by p53 after stress and whose
reduction induces the release the autophagic protein beclin-1 from
sequestration by Bcl-2, Bcl-xL and Mcl-1. The same mechanism can
work via transcriptional induction of the proteins Bax, Bad and
Puma [68,69].
In contrast to these autophagy-promoting functions of p53 in
the nucleus, the cytoplasmic pool of p53 suppresses autophagy
in several model organisms as demonstrated by the fact that phar-
macological inhibition of p53 can trigger autophagy in cytoplasts
[70] (Fig. 3). Interestingly, in human, mouse and nematode cells
depletion or inactivation of p53 by different means induced
autophagy relying on mTOR inhibition. Another demonstration of
this p53 cytoplasmic activity is the fact that canonical inducersMacroautophagy
sponse. (A) By interacting with clathrin heavy chain wild type p53 fosters EGFR
er hand mutant p53 promotes the recycling of internalized EGFR by sustaining RCP-
ic p53 interacts with rate-limiting enzymes of glycolysis and pentose phosphate
sters ROS production, an effect augmented by the inhibition of MnSOD activity at
reported for the transcriptional activity; mechanistic insights for this inhibition are
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and this degradation can be counteracted by the inhibition of
either MDM2 or of the proteasome. In line with this, restoration
of cytoplasmic p53 in p53-deﬁcient HCT116 cells can inhibit
autophagy induction. Notably, this inhibition is cell cycle depen-
dent and causes autophagy mostly in the G0/G1 phase [70]. The
meaning of the divergence of nuclear and cytoplasmic p53 effects
on autophagy is still controversial. By inducing the activation of the
protein DRAM, p53 could favor cell death (DRAM is required for
p53-dependent cell-death) or counteract it (autophagy induction
can substitute apoptosis in the response to stress). In this context
it has been demonstrated that in many cell types wild type p53
confers increased survival upon chronic starvation by post-trans-
criptionally downregulating microtubule-associated protein 1 A/
lB-light chain 3 (LC3), a key component of the autophagic machin-
ery [71].
5. Regulation of vesicles and membranes trafﬁcking by p53
The process of endocytic membrane trafﬁcking which involves
cellular internalization and sorting of molecules, plasma mem-
brane proteins and lipids, is essential for a variety of biological
functions (e.g. nutrient uptake, cell adhesion and migration, recep-
tor signaling and recycling, pathogen entry, cell polarity and fate)
and is subverted in cancer cells [72].
p53 may affect the endocytic compartment in different ways.
Indeed, p53 physically interacts with proteins like NUMB, an endo-
cytic factor asymmetrically partitioned at stem cell mitosis and
determining daughter cells fate [73]. In somatic stem cells (SC),
p53 was shown to counteract stem cell expansion by several mech-
anisms, including block of reprogramming of somatic/progenitor
cells into SC [74] and by imposing an asymmetric mode of self-
renewing divisions in mammary and neural SC [75,76]. Even if
p53 localization was not investigated in these studies, a possible
involvement of p53 in the initial process of asymmetric cell divi-
sion, likely by cytoplasmic positioning, can be envisaged. Undoubt-
edly, the roles of nuclear and cytoplasmic p53 in regulating normal
and cancer stem cell niche homeostasis are worth to be investi-
gated in depth in the future.
A key step in the process of endocytosis is the establishment of
clathrin-coated vesicles to select receptors for internalization.
Notably, in unstressed conditions, cytoplasmic p53 has been
shown to interact with clathrin heavy chain (CHC) to regulate
the endocytosis of epidermal growth factor receptor (EGFR). In
response to EGF stimulation, wild type p53, but not mutant p53,
has been found to localize at plasma membrane interacting with
CHC. This event promotes EGFR internalization and alters its
related signal transduction [77]. Intriguingly the association of
clathrin with wild type p53 has also been found in the nucleus,
where it increases the transactivation functions of p53 [78]. This
role of p53 on endocytosis may represent another important layer
of its oncosuppressive activities in the cytoplasm and it is not
excluded that this regulation may happen also for other receptors.
Further investigations on these aspects is however required. Inter-
estingly pro-oncogenic mutant forms of p53 have been found to
possess endocytosis-related gain-of-function activity contributing
to aberrant migration. Indeed, Muller et al. demonstrated that
mutant p53 governs the recycling of EGFR and integrins by
enhancing the binding of the RAB-coupling protein (RCP) to recy-
cling endosomes thus promoting the plasma-membrane localiza-
tion of EGFR and integrins [79].
Different studies are beginning to unveil a role of p53 in regu-
lating vesicle trafﬁcking that is more complex than this, at least
from a nuclear perspective. Vesicle trafﬁcking is profoundly
affected by lipid metabolism. In an elegant work, Prives and col-
leagues found that some mutant p53 gain the ability to interactwith SREBP family of transcription factors, leading to their aberrant
activation [80]. This event has the consequence of fostering the ﬂux
of mevalonate pathway with increase in lipid biosynthesis and pro-
tein geranyl-geranylation that, in turn, impinges on several onco-
genes such as YAP and TAZ [81]. Since RAB proteins require
prenylation for proper membrane localization, the positive effect
of mutant p53 on the mevalonate pathway could contribute to
the observed effect on receptor recycling. Moreover, beyond recep-
tor internalization, mutant p53 has also been reported to control
the glucose inﬂux stimulating glucose transporters (GLUT1) trans-
location to the plasma membrane by promoting the RhoA/ROCK/F-
actin axis [82].6. Regulation of cell metabolism, oxidative stress and
antioxidant response by p53
In addition to being fundamental for normal cell survival, the
regulation of cell metabolism has recently emerged to play an
important role in cancer. Tumor cells indeed display particular
metabolic needs connected to their high proliferative rate, and
consume large quantities of glucose. In fact it has been demon-
strated that cancer cells primarily use glycolysis for ATP produc-
tion, even in the presence of adequate oxygen and this metabolic
signature, named ‘‘Warburg effect’’, enables cancer cells to direct
glucose to macromolecules biosynthesis, supporting their rapid
growth [83]. In the recent years, the concept that p53 can directly
regulate glucose metabolism and oxidative phosphorylation has
emerged [84–86].
The activity of p53 in metabolism involves several aspects
spanning from oxidative stress regulation to the orchestration of
glucose metabolism [85]. These p53 actions result from a coordina-
tion of transcriptional and cytoplasmic activities, whose net
balance is not always easy to understand. Regarding the mitochon-
drial energetic regulation, p53 is able to promote both tricarboxylic
acid cycle (TCA) and oxidative phosphorylation (OXPHOS). For the
TCA cycle, p53 reduces the expression of the pyruvate dehydroge-
nase kinase isoenzyme-2 (Pdk2), which favors the ﬂux of pyruvate
to acetyl-CoA [87]. Moreover, p53 also regulates glutaminolysis by
activating the expression of mitochondrial glutaminase (GLS2),
which promotes glutamine to glutamate conversion leading to
the formation of a-ketoglutarate, a TCA cycle intermediate
[88,89]. As for mitochondrial respiratory chain, p53 is able to foster
the pathway by transcriptionally activating synthesis of cyto-
chrome c oxidase 2 (SCO2) expression, a regulator of complex IV
[90], cytochrome c oxidase (COX) I subunit, and AIF, essential for
mitochondrial respiratory complex I function [91,92]. The reactive
oxygen species produced by the enhancement of OXPHOS could be
detrimental for cell survival, thus p53 upregulates antioxidant
activities inducing the transcription of antioxidant targets such
as GPX1, MnSOD, ALDH4, TPP53INP1, GLS2, the sestrins
[65,88,89,93,94] and the TP53-induced glycolysis and apoptosis
regulator, TIGAR. By limiting the activity of Phosphofructokinase
1 (PFK1), TIGAR reduces the rate of glycolysis while promoting
pentose phosphate pathway (PPP) [95] (Fig. 3).
The PPP is a central metabolic pathway that produces NADPH
required for regeneration of reduced glutathione (GSH). Interest-
ingly, it has been recently demonstrated that a pool of cytoplasmic
p53 can inhibit glucose-6-phosphate dehydrogenase (G6PDH), the
rate-limiting enzyme of PPP, through transient interactions [96]
(Fig. 3). In line with this, it was demonstrated that p53 is able to
bind the antioxidant enzyme MnSOD in the mitochondrial matrix
and inhibit its activity [97], thus fostering the propagation of oxi-
dative stress [97].
The net effect of nuclear and cytoplasmic activity is not clear
and may be cell context and stress-dependent. In HCT116 colon
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fore raise NADPH levels. It is conceivable that in cancer cells inac-
tivation of p53 by different means accelerates glucose
consumption and directs glucose for rapid production of macro-
molecules by an increase in PPP ﬂux thus enhancing biosynthesis.
In turn p53 loss could also contribute to the Warburg effect by fos-
tering glycolysis; indeed p53 can negatively regulate, through the
control of translation or protein stability, the phosphoglycerate
mutase (PGM) thus reducing the glycolytic rate [98].
7. The cytoplasmic p53’s activities and pathophysiology
The pathophysiological relevance of the p53’s transcription-
independent activities in vivo has been unveiled by some pivotal
studies in animals. The classic model of p53-induced cell death is
the apoptosis following c-irradiation. Irradiation treatments on
mouse ﬁbroblast revealed that transcription-independent apopto-
sis is the ﬁnal determinant of cell death [11]. The group of Ute Moll
demonstrated that in normal mouse exposed to whole body c-irra-
diation or a single injection of a dose of etoposide there is mito-
chondrial p53 accumulation in radiosensitive organs like thymus,
spleen and testis but not in radioresistant organs like liver and kid-
ney. p53 that accumulates at mitochondria in radiosensitive organs
is able to trigger a p53-dependent ﬁrst wave of caspase-3 activa-
tion within the ﬁrst hours, followed by an early wave of apoptosis
[99]. Importantly in this system the induction of p53 target genes
occurs later and gives rise to a second wave of caspase-3 activation.
Conversely, a lack of mitochondrial p53 accumulation in radiore-
sistant organs correlates with cell cycle arrest and absence of apop-
tosis [54].
The functional importance of p53 extra-nuclear activities has
been clariﬁed by the use of the two molecules piﬁthrin-a and -l.
Piﬁthrin-l (PFTl) selectively inhibits p53 mitochondrial transloca-
tion and reduces its afﬁnity to Bcl-xL and Bcl-2, without interfering
with its transcription function [100]. Piﬁthrin-a inhibits the tran-
scriptonal activity of p53 [101,102]. PFT-l treatment of mice,
before c-irradiation, was able to protect them from bone marrow
failure reducing thymocyte death [100], although transcriptional
activity was not affected.
A key hallmark of cancer is the escape from oncosuppressive
pathways such as apoptosis, autophagy and cell cycle arrest,
mainly regulated by wild type p53. In order to escape this regula-
tion cancer cells frequently bear p53 mutations (in nearly 50% of
the cases), and these mutations occur mainly in the DNA binding
domain (‘‘hotspot mutations’’) and abolish its transactivation func-
tions. Whether the presence of mutations in p53 affects its translo-
cation to the cytoplasm and its cytoplasmic and mitochondrial
functions has not been thoroughly investigated. From several stud-
ies, however, the cytoplasmic and mitochondrial localization of
mutant p53 [3,46,48,103] has emerged, even if the pattern of inter-
actions entailed by mutant p53 at the mitochondria has still not
been understood. Some transcriptionally impaired p53 mutants
(e.g. R175H, R273H, C277F) have been shown to bind Bak in vitro
and induce cytochrome c release from isolated mitochondria
[103]. This is in contrast with the proto-oncogenic role of mutant
p53, and indeed it was demonstrated that mutant p53 overexpres-
sed in human cancer cell lines, even if able to bind Bak, does not
display apoptotic activity [3]. In line with this, it was also shown
that p53 mutants are unable to interact with Bcl-2 family proteins
and thus to induce MOMP [2,3,46,48]. In general it is assumed that
such ‘‘hot spot’’ p53 mutations also affect the mitochondrial func-
tions of the protein, reducing its capacity to induce MOMP; intrigu-
ingly, however, it has been demonstrated that upon transfection in
HCT116 p53/ cells p53 mutants that are able to localize to the
cytoplasm have an intact inhibitory effect on autophagy [104].8. Clinical implications
Reactivation of wild type p53 in tumors in order to trigger
apoptosis is a promising approach for cancer therapy [105–107].
So far, the majority of screens searching for p53-reactivating com-
pounds have focused on molecules that would activate the wild
type p53-dependent transcriptional program, although the p53
transcriptional response does not necessarily lead to apoptosis
and can favor the persistence of tumor cells in the body [108].
The search for molecules that speciﬁcally activate cytoplasmic
p53 function can be therefore an attractive goal for drug develop-
ment. Several drugs that can restore transcription-dependent
apoptosis have been developed recently, starting from small mole-
cules such as PRIMA-1 that can rescue oncogenic mutants to wild
type [109,110]. Interestingly pharmacological modulation of p53
by PRIMA-1 can activate a transcription-independent apoptotic
program [52], by inducing mitochondrial localization of Bax and
consequent cytochrome c release.
Conversely, in p53 wild type tumors, compounds such as Nut-
lin-3a and RITA, lead to p53 detachment from its negative regula-
tor MDM2 thus unleashing its pro-apoptotic activity [105,106].
Although the apoptotic effects of Nutlin-3a and RITA have been ini-
tially linked exclusively to the transcriptional activities of p53 in
the nucleus, it has recently emerged how the transcription-inde-
pendent activity of p53 could be a major contributor to the apop-
tosis induced by these drugs, at least in some cell lines [9,111].
Indeed, Vaseva and others found that p53 rapidly translocates to
the mitochondria after treatment of cells with Nutlin-3a, and acti-
vates a pro-apoptotic signal that is strongly independent from its
transcriptional activities [111–114]. Yet, we found that RITA, due
to its ability in promoting HIPK2 activation and consequent
p53Ser46 phosphorylation, efﬁciently triggers apoptosis even
without transcriptional cell activity [9,115]. A high number of
newmolecules able to unleash or restore p53 transcriptional activ-
ity have been discovered over the last years [116]; it is important
to consider that also for these molecules, as happened for Nutlin-
3a and RITA, p53-dependent transcription-independent oncosup-
pressive activities could be unveiled, thus providing new tools
for cancer therapy.
Another possible therapeutic approach, which may exploit the
gene therapy technology, could be the speciﬁc delivery to the cells
of p53 engineered to localize at mitochondria. This is the case of
Lp53wt, generated by fusion of the import leader sequence of orni-
thine transcarbamylase to the N-terminus of p53 [117–119].
Lp53wt is able to interact with Bcl-xL and is imported in the mito-
chondrial matrix where the leader is cleaved off and the protein is
redistributed in the mitochondria. Interestingly although unable to
induce transcription, Lp53wt is capable of promoting transcription-
independent apoptosis in p53-null human cancer cell lines [12] .
9. Future perspectives
Notwithstanding the growing number of papers reporting evi-
dences of the oncosuppressive role of p53 in the cytoplasm, several
aspects have not been clariﬁed and some data remain elusive. One
of the main points that need to be elucidated regards the co-regu-
lation of the nuclear and the cytoplasmic routes of p53 activation.
Indeed these two arms are tightly coordinated as demonstrated by
the fact that both pathways can be triggered by the same stimuli
in vitro and in vivo leading to their simultaneous activation. A
major drawback of the approaches inspecting p53 roles in the cyto-
plasm is that the mechanisms have been primarily elucidated by
in vitro studies, in artiﬁcial settings that have often led to contro-
versial results. Dissecting these mechanistic aspects in vivo could
help to clarify the real sequence of biochemical events by which
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An intriguing point of investigation is whether in vivo differences
in the type and strength of the biological and pharmacological
stimuli could imbalance p53 activity towards one of these speciﬁc
routes. This could be of particular relevance in terms of exploiting
the p53 mitochondrial route for therapeutic intervention. Indeed
transcriptional activation of p53 in response to oncogenic stress
and chemotherapy could lead to cell cycle arrest and senescence
instead of leading to more desired outcomes such as apoptosis
and necrosis. Several reports, in fact, have underlined the possible
negative impact of p53-induced senescence on chemotherapy
response [120], while it has been found that inactivation of p53
transcriptional activity by mutations [121] or mitochondrial
sequestration [12] favors apoptotic response and tumor cell clear-
ance. Moreover, the ﬁeld needs to move toward clarifying the real
capability of missense p53 mutants to regulate mitochondrial
apoptosis. The same should be done for the several isoforms of
p53 found in mammalian cells, many of which are transcriptionally
inactivated or cytoplasm-localized [122]. Despite, from a mecha-
nistic point of view, a lot of effort has been done in deﬁning the
critical steps of p53 extra-nuclear activities, the localization and
timing of the post-translational modiﬁcations (ubiquitylation,
phosphorylation, acetylation) affecting p53 translocation and their
real role in vivo still remain an open issue.
Apart from apoptosis, there is a relevant lack of knowledge on
how p53 orchestrates autophagy and metabolism in the cytoplasm
and in particular on how extra nuclear activities are coordinated
with the transcriptional response. Indeed the real ﬁnal outcome
derived from this interplay and how this could impact on tumori-
genesis and cancer therapy is still controversial.
To date, all the evidences point towards a role of p53 in tumor
suppression, that goes well beyond its role as a nuclear resident
transcription factor. For this reason a ﬁne dissection of p53 interac-
tions, modiﬁcations and subcellular localization in the cytoplasm
may still reserve new unexpected aspects of this extensively stud-
ied protein and provide a rationale for therapeutic intervention.
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